Home/Filings/4/0001209191-22-014172
4//SEC Filing

Fontenot Jason D. 4

Accession 0001209191-22-014172

CIK 0001001233other

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 5:18 PM ET

Size

14.9 KB

Accession

0001209191-22-014172

Insider Transaction Report

Form 4
Period: 2022-02-25
Fontenot Jason D.
SVP, Chief Scientific Officer
Transactions
  • Tax Payment

    Common Stock

    2022-02-25$5.90/sh6,248$36,86358,893 total
  • Award

    Common Stock

    2022-02-25+45,100103,993 total
  • Award

    Stock Option (Right to Buy)

    2022-02-25+121,770121,770 total
    Exercise: $5.90Exp: 2032-02-24Common Stock (121,770 underlying)
Footnotes (6)
  • [F1]Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
  • [F2]Includes: (a) 7,565 shares resulting from the February 25, 2022 sole annual vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 6,304 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 8,335 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (c) 5,548 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 14,667 shares subject to such RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (see footnote 3)
  • [F3](d) 3,334 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F4]Includes 1,953 shares acquired on April 30, 2021 and 692 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.
  • [F5]Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F6]One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Issuer

SANGAMO THERAPEUTICS, INC

CIK 0001001233

Entity typeother

Related Parties

1
  • filerCIK 0001851761

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 5:18 PM ET
Size
14.9 KB